Vir Biotechnology, Inc. is an immunology company, which is focused on combining cutting-edge technologies to treat and prevent serious infectious diseases and other serious conditions. The Company's clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). It also has several preclinical candidates in its pipeline including those targeting influenza A and B, COVID-19, respiratory syncytial virus and human metapneumovirus (RSV and MPV), and human papillomavirus (HPV). The Company's pipeline includes VIR-1949, VIR-7229, VIR-2981, VIR-8190, and HIV Cure. It also engaged in developing tobevibart, a monoclonal antibody also known as VIR-3434, and Elebsiran, an siRNA also known as VIR-2218, for the treatment and suppression of chronic HDV. Its Elebsiran is an investigational HBV-targeted siRNA that reduces HBsAg, a protein which is required for the HDV viral life cycle.

Employees

367

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
16/03/26	9.750 $	+5.29%	1,413,604
13/03/26	9.260 $	-2.32%	2,612,536
12/03/26	9.480 $	-3.46%	3,784,269
11/03/26	9.820 $	-0.61%	3,825,789
10/03/26	9.880 $	+0.82%	3,246,469

Delayed Quote Nasdaq

More quotes

Income Statement and Estimates

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

9.260USD

Average target price

20.78USD

Spread / Average Target

+124.38%

Consensus

EPS Estimates

Revisions to estimates

Quarterly revenue - Rate of surprise

Company calendar

Real-time Estimate Cboe BZX Other stock markets 18:33:37 16/03/2026 GMT			5-day change	1st Jan Change
9.820 ^USD	+6.05%		-0.51%	+61.69%

03-04	Vir Biotechnology appoints Marianne De Backer as president in addition to CEO on March 4, 2026 - SEC filing	RE
03-04	Vir Biotechnology, Inc. Appoints Marianne De Backer as President	CI

Capitalization	1.48B 1.29B 1.17B 1.11B 2.03B 137B 2.1B 13.87B 5.51B 65.36B 5.55B 5.44B 236B	P/E ratio 2026 *	-6.68x	P/E ratio 2027 *	-4.34x
Enterprise value	1.17B 1.02B 922M 880M 1.6B 108B 1.66B 10.96B 4.36B 51.66B 4.39B 4.3B 186B	EV / Sales 2026 *	4.79x	EV / Sales 2027 *	9.06x
Free-Float	88.1%	Yield 2026 *	-	Yield 2027 *	-

03-04	Vir Biotechnology appoints Marianne De Backer as president in addition to CEO on March 4, 2026 - SEC filing	RE
03-04	Vir Biotechnology, Inc. Appoints Marianne De Backer as President	CI
02-26	Top Premarket Decliners	MT
02-26	Vir Biotechnology announces pricing of public offering of common stock at $8.50 per share	RE
02-24	Wall Street Consolidates After Losses Fueled by Tariff Uncertainties as US Equity Futures Post Narrow Gains Pre-Bell	MT
02-24	Raymond James Upgrades Vir Biotechnology to Strong Buy From Outperform, Adjusts Price Target to $19 From $12	MT
02-24	Top Premarket Gainers	MT
02-24	Vir Biotechnology, Astellas to Advance Prostate Cancer Treatment; Says Phase 1 Trial Shows 'Promising' Anti-Tumor Activity	MT
02-24	Vir Biotechnology, Inc., Q4 2025 Earnings Call, Feb 23, 2026
02-23	Vir Biotechnology, Astellas in $335 Million Licensing Deal for Prostate Cancer Treatment	DJ
02-23	Astellas & Vir Biotechnology collaborate to advance VIR-5500	RE
02-23	Vir Biotechnology Q4 Loss Narrows, Revenue Rises	MT
02-23	Vir Biotechnology reports positive updated phase 1 results for PSMA-targeting, Pro-Xten dual-masked T-cell engager VIR-5500	RE

02-24	Raymond James Upgrades Vir Biotechnology to Strong Buy From Outperform, Adjusts Price Target to $19 From $12	MT
11-03	Vir Biotechnology, Inc. Announces Completion of Enrollment in ECLIPSE 1 Phase 3 Trial for Chronic Hepatitis Delta	CI
27/08/25	Vir Biotechnology Shares Rise After Upgrade From BofA Securities	MT
27/08/25	BofA Securities Upgrades Vir Biotechnology to Buy From Neutral, Price Target is $14	MT
06/08/25	Vir Biotechnology Q2 revenue misses expectations, net loss narrows	RE

Vir Biotechnology, Inc. Share Price

Equities

VIR

US92764N1028

Biotechnology & Medical Research

Valuation: Vir Biotechnology, Inc.

Chart: Vir Biotechnology, Inc.

Latest news: Vir Biotechnology, Inc.

Last Transcript: Vir Biotechnology, Inc.

Analysts' recommendations: Vir Biotechnology, Inc.

Press Releases: Vir Biotechnology, Inc.

News in other languages: Vir Biotechnology, Inc.

Quotes and Performance

Course Extremes

Managers and Directors: Vir Biotechnology, Inc.

ETFs: Vir Biotechnology, Inc.

Other Biotechnology & Medical Research

Financials

Company Profile

Quotes

Income Statement and Estimates

Analysts' Consensus

Quarterly revenue - Rate of surprise

03-05	Next-Generation Cancer Therapies Post Breakthrough Results Across Multiple Tumor Types	AQ
02-26	Vir Biotechnology to Participate in Upcoming Investor Conferences	BU
02-26	Vir Biotechnology Announces Pricing of Public Offering of Common Stock	AQ
02-24	Vir Biotechnology Announces Proposed Public Offering of Common Stock	BU
02-24	Vir Biotechnology Reports Positive Updated Phase 1 Results for PSMA-targeting, PRO-XTEN(R) Dual-masked T-Cell Engager VIR-5500 in Patients with Metastatic Prostate Cancer	AQ

02-25	USA-Les valeurs à suivre à Wall Street (actualisé)
02/08/24	Sanofi : accord de licence exclusif avec Vir Biotechnology
29/01/24	USA-Les valeurs à suivre à Wall Street (actualisé)
15/09/22	La OMS "desaconseja enérgicamente" el uso de dos tratamientos contra el COVID
22/08/22	USA-Les valeurs à suivre à Wall Street (actualisé)

1 day	+6.16%
1 week	-0.51%
Current month	+7.26%
1 month	+30.00%
3 months	+50.46%
6 months	+100.62%
Current year	+61.69%

1 week	9.12	10.29
1 month	7.26	10.94
Current year	5.55	10.94
1 year	4.16	10.94
3 years	4.16	27.48
5 years	4.16	58.34
10 years	4.16	141.01

Manager	Title	Age	Since
Marianne de Backer CEO	Chief Executive Officer	57	02/04/2023
Jason O’Byrne DFI	Director of Finance/CFO	57	01/10/2024
Jennifer Towne CTO	Chief Tech/Sci/R&D Officer	-	05/11/2023

Director	Title	Age	Since
Vicki Sato CHM	Chairman	77	30/11/2016
Robert More BRD	Director/Board Member	58	31/08/2016
Sona Saira Ramasastry BRD	Director/Board Member	50	31/08/2019

Name	Varia. Jan 1.	Weight	AuM
AGF U.S. MARKET NEUTRAL ANTI-BETA FUND - USD	-1.11%	12.9%	253 M€
HARTFORD MULTIFACTOR SMALL CAP ETF - USD	+3.05%	0.63%	30 M€
ROYCE QUANT SMALL-CAP QUALITY VALUE ETF - USD	+0.68%	0.58%	20 M€

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi.($)
VIR BIOTECHNOLOGY, INC.	+6.05%	-0.51%	+39.19%	-59.68%	1.48B
LONZA GROUP AG	+0.27%	-3.29%	-13.88%	-10.15%	42.78B
BEONE MEDICINES AG	+1.18%	-4.42%	+9.00%	+28.54%	31.5B
CELLTRION, INC.	-2.68%	-5.88%	+11.77%	+44.44%	29.99B
IQVIA HOLDINGS INC.	+0.06%	-7.79%	-10.96%	-16.19%	27.65B
REVOLUTION MEDICINES, INC.	+4.84%	-0.84%	+152.88%	+344.92%	18.8B
ASCENDIS PHARMA A/S	+2.13%	-4.08%	+36.30%	+109.80%	13.87B
MEDPACE HOLDINGS, INC.	+0.90%	-4.96%	+39.37%	+149.54%	12.78B
EUROFINS SCIENTIFIC SE	-0.33%	-3.53%	+22.17%	-0.65%	12.39B
IONIS PHARMACEUTICALS, INC.	+1.90%	-3.76%	+111.46%	+107.23%	11.76B
Average	+1.50%	-4.45%	+39.73%	+69.78%	20.3B
Weighted average by Cap.	+0.75%	-4.60%	+25.93%	+61.25%

	2026 *	2027 *
Net sales	244M 212M 192M 184M 334M 22.52B 346M 2.29B 908M 10.78B 916M 896M 38.87B	123M 107M 96.82M 92.37M 168M 11.33B 174M 1.15B 457M 5.42B 461M 451M 19.56B
Net income	-189M -165M -149M -142M -259M -17.45B -268M -1.77B -704M -8.35B -709M -694M -30.11B	-346M -302M -273M -260M -474M -31.96B -491M -3.24B -1.29B -15.29B -1.3B -1.27B -55.15B
Net Debt	-310M -270M -245M -233M -425M -28.64B -440M -2.91B -1.16B -13.7B -1.16B -1.14B -49.43B	-368M -320M -290M -277M -503M -33.96B -522M -3.45B -1.37B -16.25B -1.38B -1.35B -58.61B